Neuromyelitis Optica Spectrum Disorder

Disease State Hub

FDA Alerts

FDA

FDA

FDA Approves Treatment for Neuromyelitis Optica Spectrum Disorder

08/17/2020

The US Food and Drug Administration has approved a new treatment for neuromyelitis optica spectrum disorder among adults with the AQP4 antibody.

08/17/2020

Research Summaries

Research Summary

Research Summary

Nationwide Analysis of the Occurrence of Neuromyelitis Optica in Patients With Autoimmune Disorders

09/24/2024

Jessica Ganga

Researchers aimed to find the occurrence of neuromyelitis optica in patients with systemic lupus erythematosus and primary Sjögren syndrome.

09/24/2024

Research Summary

Patients With Double-Antibody Seronegative NMOSD Experience Severe Retina Damage After Optic Neuritis

09/16/2024

Anthony Calabro, MA

Researchers set out to determine how the retina was impacted by double-antibody seronegative neuromyelitis optica spectrum disorder.

09/16/2024

Research summary

Early Serologic Diagnosis of AQP4+ NMOSD Based on Clinical Factors

08/22/2024

Jessica Ganga

In a multicenter, retrospective study, researchers evaluated time from NMOSD onset to serological diagnosis and factors associated with predicting shorter time to diagnosis.

08/22/2024

Research summary

Research summary

Anxiety, Depression Prevalent in Patients Diagnosed With NMOSD

07/23/2024

Anthony Calabro, MA

A team of researchers sought to determine the prevalence of depression and anxiety in patients with NMOSD before their diagnosis of the disease.

07/23/2024

Research Summary

Meta-Analysis Highlights Clinical Differences Between Patients With NMOSD, MS

06/11/2024

Anthony Calabro, MA

A systematic review and meta-analysis examined the clinical differences between adult patients with neuromyelitis optica spectrum disorders and those with multiple sclerosis.

06/11/2024

October 2024

Current Issue

October 2024

Volume 64

Issue 9